Stockscreener 앱 받기
1.04
0.95%
-0.01
시간 외 거래:
1.05
0.01
+0.96%
전일 마감가:
$1.05
열려 있는:
$1.04
하루 거래량:
3.66M
Relative Volume:
0.93
시가총액:
$227.48M
수익:
$95,000
순이익/손실:
$-327.27M
주가수익비율:
-0.4906
EPS:
-2.12
순현금흐름:
$-239.25M
1주 성능:
-3.70%
1개월 성능:
-13.33%
6개월 성능:
-31.13%
1년 성능:
-55.93%
1일 변동 폭
$1.01
$1.105
1주일 범위
$0.9842
$1.19
52주 변동 폭
$0.8621
$3.78
Allogene Therapeutics Inc Stock (ALLO) Company Profile
명칭
Allogene Therapeutics Inc
전화
(650) 457-2700
주소
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
ALLO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
1.04 | 231.85M | 95,000 | -327.27M | -239.25M | -2.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-14 | 다운그레이드 | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | 업그레이드 | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-08-08 | 재개 | Oppenheimer | Outperform |
| 2024-05-31 | 개시 | Piper Sandler | Overweight |
| 2024-01-05 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-01-05 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-08 | 개시 | Citigroup | Buy |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2023-01-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-01-06 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-12-12 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2022-08-10 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-07-15 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-06-03 | 개시 | Robert W. Baird | Neutral |
| 2022-02-28 | 재확인 | B. Riley Securities | Buy |
| 2021-10-20 | 개시 | Cowen | Outperform |
| 2021-10-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-10-08 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-09-23 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2021-06-21 | 재개 | Jefferies | Buy |
| 2021-05-20 | 업그레이드 | Truist | Hold → Buy |
| 2021-05-14 | 개시 | B. Riley Securities | Buy |
| 2021-01-26 | 업그레이드 | Stifel | Hold → Buy |
| 2020-12-10 | 재개 | H.C. Wainwright | Buy |
| 2020-11-24 | 개시 | BofA Securities | Buy |
| 2020-10-23 | 개시 | RBC Capital Mkts | Outperform |
| 2020-06-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-05-29 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-19 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2020-05-15 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-05-14 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-14 | 다운그레이드 | SunTrust | Buy → Hold |
| 2020-04-13 | 개시 | SunTrust | Buy |
| 2020-03-13 | 개시 | H.C. Wainwright | Buy |
| 2020-03-05 | 개시 | Stifel | Hold |
| 2020-02-24 | 개시 | Berenberg | Hold |
| 2019-12-18 | 개시 | JMP Securities | Mkt Outperform |
| 2019-11-04 | 개시 | Canaccord Genuity | Buy |
| 2019-08-09 | 개시 | BTIG Research | Buy |
| 2019-06-05 | 개시 | ROTH Capital | Neutral |
| 2019-05-31 | 개시 | Guggenheim | Neutral |
| 2019-05-23 | 개시 | Stifel | Hold |
| 2019-03-29 | 개시 | Piper Jaffray | Overweight |
모두보기
Allogene Therapeutics Inc 주식(ALLO)의 최신 뉴스
Will Allogene Therapeutics Inc. benefit from macro trendsMulti-Year Investment Performance Summary Report - Newser
Allogene Therapeutics Inc. stock trend forecastMarket Stability and Long-Term Growth Outlook - Newser
Volume spikes in Allogene Therapeutics Inc. stock – what they meanDaily Trade Monitor with Pattern Alerts - Newser
Can trapped investors hope for a rebound in Allogene Therapeutics Inc.Smart Trend Analysis With Buy Point Cues - Newser
Allogene Therapeutics shares rise 2.86% after-hours following Sumitomo Pharma's submission for Parkinson's disease treatment. - AInvest
Is Allogene Therapeutics Inc. meeting your algorithmic filter criteriaPre-Market Stock Movement Summary and Review - Newser
Follicular Lymphoma Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsights | AstraZeneca, InnoCare Pharma, Allogene Therapeutics, HUTCHMED, Sound Bio - Barchart.com
Allogene Therapeutics Schedules Conference Call and Webcast to Discuss Q2 2025 Financial Results on August 13 - Quiver Quantitative
Allogene Therapeutics announces Q2 2025 financial results, conference call on August 13. - AInvest
Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update - Stock Titan
How to integrate Allogene Therapeutics Inc. into portfolio analysis toolsFree Breakout Entry Signal Confirmation Tool - Newser
Allogene Therapeutics shares fall 1.36% intraday after Sumitomo Pharma and RACTHERA submit application for Parkinson's disease treatment. - AInvest
What makes Allogene Therapeutics Inc. stock price move sharplyEquity Signal Recap With Long-Term Summary - Newser
JMP Securities Reiterates Market Perform Rating for Allogene Therapeutics Inc. - AInvest
Allogene Therapeutics Maintains Buy Rating Amid Strategic Adjustments and Technological Advancements - AInvest
Patient Dies After Receiving Monoclonal Antibody Lymphodepletion Regimen in LBCL Trial for Allogene’s Cema-Cel - CGTLive®
Allogene Sticks With Standard Lymphodepletion In CAR-T Trial After Patient Death - insights.citeline.com
Allogene stock maintains Market Perform rating at Citizens JMP after trial adjustment - Investing.com Canada
Allogene stock continues ALPHA3 trial with standard FC regimen after safety event - Investing.com Canada
Allogene Scraps Immunosuppressive Antibody After Patient Death in Lymphoma Trial - BioSpace
This AvalonBay Communities Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday - Benzinga
Patient death in Allogene trial - The Pharma Letter
What is Allogene Therapeutics Inc. company’s growth strategyBuild wealth steadily with proven investment strategies - Jammu Links News
What are the technical indicators suggesting about Allogene Therapeutics Inc.High-yield growth strategies - Jammu Links News
When is Allogene Therapeutics Inc. stock expected to show significant growthInvest confidently with market-leading analysis - Jammu Links News
How does Allogene Therapeutics Inc. compare to its industry peersMaximize your portfolio’s growth potential - Jammu Links News
Is it the right time to buy Allogene Therapeutics Inc. stockJaw-dropping returns - Jammu Links News
Is Allogene Therapeutics Inc. stock overvalued or undervaluedMaximize returns with disciplined investment techniques - Jammu Links News
What drives Allogene Therapeutics Inc. stock priceStrong return on assets - Jammu Links News
What are Allogene Therapeutics Inc. company’s key revenue driversUnstoppable profit momentum - Jammu Links News
How many analysts rate Allogene Therapeutics Inc. as a “Buy”Access daily stock market expert updates - Jammu Links News
What is the dividend policy of Allogene Therapeutics Inc. stockGet real-time alerts on high-potential stocks - Jammu Links News
What are the latest earnings results for Allogene Therapeutics Inc.Jaw-dropping returns - Jammu Links News
How volatile is Allogene Therapeutics Inc. stock compared to the marketBeginner Investor Report With Low Risk - Jammu Links News
Allogene Therapeutics Faces Market Volatility Amid Financial Challenges - StocksToTrade
Allogene Resets Clinical Course After Patient Death In Lymphoma StudyAllogene Therapeutics (NASDAQ:ALLO) - Benzinga
Regeneron cancer bispecific rejected again; Allogene discloses trial death - BioPharma Dive
Allogene Therapeutics updates ALPHA3 trial protocol following safety event By Investing.com - Investing.com India
Allogene Therapeutics updates ALPHA3 trial protocol following safety event - Investing.com
Allogene Therapeutics Adjusts ALPHA3 Trial After Adverse Event - TipRanks
RENT Form 144: Insider plans to sell 262 shares worth $1.49k | ALLO SEC FilingForm 8-K - Stock Titan
Allogene Therapeutics Announces Selection of Standard FC Lymphodepletion Regimen in ALPHA3 Study Following Consultation with FDA and Safety Board - Quiver Quantitative
Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma - The Manila Times
Allogene says lymphodepletion drug caused patient death, changes CAR-T study design - Endpoints News
Allogene Therapeutics shares rise 2.33% premarket after Robbins LLP class action filing. - AInvest
Understanding Allogene Therapeutics Inc.’s price movementCommunity Entry Consensus Trade Ideas Shared - metal.it
Allogene Therapeutics Inc. Trading Near Value Zone — Recovery AheadWatchlist for Low Risk High Return Stocks Updated - metal.it
RSI Crosses Above 30 for Allogene Therapeutics Inc. — Reversal in SightLow Volatility Stable Growth Picks Rank High - metal.it
Published on: 2025-07-29 12:47:04 - metal.it
CAR-T Cell Therapy Market is projected to grow to US$ 20.4 billion - openPR.com
Allogene Therapeutics Inc. Forms Bullish Flag — Upside AheadLow Drawdown Real Time Trading Tips Shared - metal.it
Allogene Therapeutics Inc (ALLO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):